CD274 and esophageal squamous cell carcinoma: Median OS in ESCC was prolonged with pembrolizumab (8.2 months versus 7.1 months; HR, 0.78 [95% CI, 0.63 to 0.96]; P = .0095) in patients with PD-L1 CPS (combined positive score) ≥ 10 with fewer treatment-related AE (18.2% versus 40.9% experienced grade 3–5 AE).